{"entity":{"type":"insider","cik":"0001453356","url":"/insider/0001453356","json_url":"/insider/0001453356.json","name":"10X Fund, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":60,"n_filings":36,"first":"2013-10-09","last":"2025-12-18","span_basis":"filed_date"},"name_variants":[{"name":"10X Fund, L.P.","source":"filing","n_filings":36,"first_seen":"2013-10-09","last_seen":"2025-12-18"}],"transactions":[{"id":4965735,"accession":"0001493152-25-028303","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-25-028303","line_url":"/filing/0001493152-25-028303#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30681.0,"shares_display":"30,681","price_per_share":6.66,"price_display":"6.66","price_state":"stated","total_value":204335.46,"total_display":"204,335.46","total_whole":"204,335","shares_owned_after":5614457.0,"shares_owned_after_display":"5,614,457","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-16","filed_date":"2025-12-18","scope":"insider"},{"id":9290354,"accession":"0001493152-25-026587","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-25-026587","line_url":"/filing/0001493152-25-026587#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":132069.0,"shares_display":"132,069","price_per_share":5.73,"price_display":"5.73","price_state":"stated","total_value":756755.37,"total_display":"756,755.37","total_whole":"756,755","shares_owned_after":5670138.0,"shares_owned_after_display":"5,670,138","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-03","filed_date":"2025-12-08","scope":"insider"},{"id":4218032,"accession":"0001493152-25-026204","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-25-026204","line_url":"/filing/0001493152-25-026204#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":120000.0,"shares_display":"120,000","price_per_share":5.73,"price_display":"5.73","price_state":"stated","total_value":687600.0,"total_display":"687,600.00","total_whole":"687,600","shares_owned_after":5682207.0,"shares_owned_after_display":"5,682,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-03","filed_date":"2025-12-04","scope":"insider"},{"id":9290353,"accession":"0001493152-25-026587","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-25-026587","line_url":"/filing/0001493152-25-026587#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":5.47,"price_display":"5.47","price_state":"stated","total_value":164100.0,"total_display":"164,100.00","total_whole":"164,100","shares_owned_after":5802207.0,"shares_owned_after_display":"5,802,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-02","filed_date":"2025-12-08","scope":"insider"},{"id":4218027,"accession":"0001493152-25-026204","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-25-026204","line_url":"/filing/0001493152-25-026204#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":5.47,"price_display":"5.47","price_state":"stated","total_value":164100.0,"total_display":"164,100.00","total_whole":"164,100","shares_owned_after":5802207.0,"shares_owned_after_display":"5,802,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-02","filed_date":"2025-12-04","scope":"insider"},{"id":4597132,"accession":"0001493152-25-021959","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-25-021959","line_url":"/filing/0001493152-25-021959#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":5.25,"price_display":"5.25","price_state":"stated","total_value":210000.0,"total_display":"210,000.00","total_whole":"210,000","shares_owned_after":5832207.0,"shares_owned_after_display":"5,832,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-11","filed_date":"2025-11-12","scope":"insider"},{"id":4566971,"accession":"0001493152-25-019379","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-25-019379","line_url":"/filing/0001493152-25-019379","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Capital Management, LLC; 10X Fund, L.P.","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":4.936,"price_display":"4.94","price_state":"stated","total_value":246800.0,"total_display":"246,800.00","total_whole":"246,800","shares_owned_after":5872207.0,"shares_owned_after_display":"5,872,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-22","filed_date":"2025-10-24","scope":"insider","n_lines":2},{"id":4400154,"accession":"0001493152-25-017839","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-25-017839","line_url":"/filing/0001493152-25-017839#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3677.0,"shares_display":"3,677","price_per_share":3.06,"price_display":"3.06","price_state":"stated","total_value":11251.62,"total_display":"11,251.62","total_whole":"11,252","shares_owned_after":5922207.0,"shares_owned_after_display":"5,922,207","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-23","filed_date":"2025-10-10","scope":"insider"},{"id":4400147,"accession":"0001493152-25-017839","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-25-017839","line_url":"/filing/0001493152-25-017839#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21323.0,"shares_display":"21,323","price_per_share":3.06,"price_display":"3.06","price_state":"stated","total_value":65248.38,"total_display":"65,248.38","total_whole":"65,248","shares_owned_after":5925884.0,"shares_owned_after_display":"5,925,884","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-22","filed_date":"2025-10-10","scope":"insider"},{"id":9290172,"accession":"0001493152-22-022804","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-022804","line_url":"/filing/0001493152-22-022804#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001453356","owner_name":"10X Fund, L.P.","owner_display_name":"10X Fund, L.P.","owner_url":"/insider/0001453356","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.087,"price_display":"2.09","price_state":"stated","total_value":20870.0,"total_display":"20,870.00","total_whole":"20,870","shares_owned_after":6168940.0,"shares_owned_after_display":"6,168,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-27","filed_date":"2022-08-15","scope":"insider"},{"id":6654384,"accession":"0001493152-22-021740","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-021740","line_url":"/filing/0001493152-22-021740#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.087,"price_display":"2.09","price_state":"stated","total_value":20870.0,"total_display":"20,870.00","total_whole":"20,870","shares_owned_after":6168940.0,"shares_owned_after_display":"6,168,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-22","filed_date":"2022-08-09","scope":"insider"},{"id":6131263,"accession":"0001493152-22-003302","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-003302","line_url":"/filing/0001493152-22-003302#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.1,"price_display":"2.10","price_state":"stated","total_value":21000.0,"total_display":"21,000.00","total_whole":"21,000","shares_owned_after":6178940.0,"shares_owned_after_display":"6,178,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-02","filed_date":"2022-02-04","scope":"insider"},{"id":6181372,"accession":"0001493152-22-001148","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-001148","line_url":"/filing/0001493152-22-001148#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.1,"price_display":"2.10","price_state":"stated","total_value":21000.0,"total_display":"21,000.00","total_whole":"21,000","shares_owned_after":6188940.0,"shares_owned_after_display":"6,188,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider"},{"id":4261401,"accession":"0001493152-21-030546","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-030546","line_url":"/filing/0001493152-21-030546#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; CZIRR JAMES C; 10X Fund, L.P.","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.37,"price_display":"2.37","price_state":"stated","total_value":23700.0,"total_display":"23,700.00","total_whole":"23,700","shares_owned_after":6198940.0,"shares_owned_after_display":"6,198,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-02","filed_date":"2021-12-06","scope":"insider"},{"id":5434979,"accession":"0001493152-21-027207","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-027207","line_url":"/filing/0001493152-21-027207#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.19,"price_display":"3.19","price_state":"stated","total_value":31900.0,"total_display":"31,900.00","total_whole":"31,900","shares_owned_after":6208940.0,"shares_owned_after_display":"6,208,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-01","filed_date":"2021-11-04","scope":"insider"},{"id":5296176,"accession":"0001493152-21-025776","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-025776","line_url":"/filing/0001493152-21-025776#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC; CZIRR JAMES C","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.37,"price_display":"3.37","price_state":"stated","total_value":33700.0,"total_display":"33,700.00","total_whole":"33,700","shares_owned_after":6218940.0,"shares_owned_after_display":"6,218,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-15","filed_date":"2021-10-19","scope":"insider"},{"id":4789374,"accession":"0001493152-21-024757","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-024757","line_url":"/filing/0001493152-21-024757#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.62,"price_display":"3.62","price_state":"stated","total_value":36200.0,"total_display":"36,200.00","total_whole":"36,200","shares_owned_after":6228940.0,"shares_owned_after_display":"6,228,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-04","filed_date":"2021-10-06","scope":"insider"},{"id":4816633,"accession":"0001493152-21-021935","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-021935","line_url":"/filing/0001493152-21-021935#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC; CZIRR JAMES C","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.91,"price_display":"3.91","price_state":"stated","total_value":39100.0,"total_display":"39,100.00","total_whole":"39,100","shares_owned_after":6238940.0,"shares_owned_after_display":"6,238,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-01","filed_date":"2021-09-03","scope":"insider"},{"id":4184277,"accession":"0001493152-21-018420","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-018420","line_url":"/filing/0001493152-21-018420#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.25,"price_display":"3.25","price_state":"stated","total_value":32500.0,"total_display":"32,500.00","total_whole":"32,500","shares_owned_after":6248940.0,"shares_owned_after_display":"6,248,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-02","filed_date":"2021-08-03","scope":"insider"},{"id":5414968,"accession":"0001493152-21-016934","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-016934","line_url":"/filing/0001493152-21-016934#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.54,"price_display":"3.54","price_state":"stated","total_value":35400.0,"total_display":"35,400.00","total_whole":"35,400","shares_owned_after":6258940.0,"shares_owned_after_display":"6,258,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-09","filed_date":"2021-07-15","scope":"insider"},{"id":4420302,"accession":"0001493152-21-013547","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-013547","line_url":"/filing/0001493152-21-013547#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.91,"price_display":"3.91","price_state":"stated","total_value":39100.0,"total_display":"39,100.00","total_whole":"39,100","shares_owned_after":6268940.0,"shares_owned_after_display":"6,268,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-03","scope":"insider"},{"id":9290103,"accession":"0001493152-21-010480","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001493152-21-010480","line_url":"/filing/0001493152-21-010480#line-5","is_derivative":false,"issuer_cik":"0001453356","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001453356","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.84,"price_display":"3.84","price_state":"stated","total_value":38400.0,"total_display":"38,400.00","total_whole":"38,400","shares_owned_after":6278940.0,"shares_owned_after_display":"6,278,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-05","scope":"insider"},{"id":4723945,"accession":"0001493152-21-010442","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001493152-21-010442","line_url":"/filing/0001493152-21-010442#line-4","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; CZIRR JAMES C; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.84,"price_display":"3.84","price_state":"stated","total_value":38400.0,"total_display":"38,400.00","total_whole":"38,400","shares_owned_after":6288940.0,"shares_owned_after_display":"6,288,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-04","scope":"insider"},{"id":9290101,"accession":"0001493152-21-010480","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001493152-21-010480","line_url":"/filing/0001493152-21-010480#line-4","is_derivative":false,"issuer_cik":"0001453356","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001453356","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":5.02,"price_display":"5.02","price_state":"stated","total_value":50200.0,"total_display":"50,200.00","total_whole":"50,200","shares_owned_after":6288940.0,"shares_owned_after_display":"6,288,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-28","filed_date":"2021-05-05","scope":"insider"},{"id":9290105,"accession":"0001493152-21-010480","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001493152-21-010480","line_url":"/filing/0001493152-21-010480#line-3","is_derivative":false,"issuer_cik":"0001453356","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001453356","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":4.47,"price_display":"4.47","price_state":"stated","total_value":33525.0,"total_display":"33,525.00","total_whole":"33,525","shares_owned_after":6298940.0,"shares_owned_after_display":"6,298,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-26","filed_date":"2021-05-05","scope":"insider"},{"id":4723943,"accession":"0001493152-21-010442","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001493152-21-010442","line_url":"/filing/0001493152-21-010442#line-3","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; CZIRR JAMES C; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":4.47,"price_display":"4.47","price_state":"stated","total_value":33525.0,"total_display":"33,525.00","total_whole":"33,525","shares_owned_after":6298940.0,"shares_owned_after_display":"6,298,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-26","filed_date":"2021-05-04","scope":"insider"},{"id":9290104,"accession":"0001493152-21-010480","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-21-010480","line_url":"/filing/0001493152-21-010480#line-2","is_derivative":false,"issuer_cik":"0001453356","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001453356","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":3.95,"price_display":"3.95","price_state":"stated","total_value":19750.0,"total_display":"19,750.00","total_whole":"19,750","shares_owned_after":6306440.0,"shares_owned_after_display":"6,306,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-23","filed_date":"2021-05-05","scope":"insider"},{"id":4723941,"accession":"0001493152-21-010442","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-21-010442","line_url":"/filing/0001493152-21-010442#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; CZIRR JAMES C; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":3.95,"price_display":"3.95","price_state":"stated","total_value":19750.0,"total_display":"19,750.00","total_whole":"19,750","shares_owned_after":6306440.0,"shares_owned_after_display":"6,306,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-23","filed_date":"2021-05-04","scope":"insider"},{"id":9290102,"accession":"0001493152-21-010480","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-010480","line_url":"/filing/0001493152-21-010480#line-1","is_derivative":false,"issuer_cik":"0001453356","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001453356","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":3.52,"price_display":"3.52","price_state":"stated","total_value":17600.0,"total_display":"17,600.00","total_whole":"17,600","shares_owned_after":6311440.0,"shares_owned_after_display":"6,311,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-22","filed_date":"2021-05-05","scope":"insider"},{"id":4723939,"accession":"0001493152-21-010442","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-010442","line_url":"/filing/0001493152-21-010442#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; CZIRR JAMES C; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":3.52,"price_display":"3.52","price_state":"stated","total_value":17600.0,"total_display":"17,600.00","total_whole":"17,600","shares_owned_after":6311440.0,"shares_owned_after_display":"6,311,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-22","filed_date":"2021-05-04","scope":"insider"},{"id":4356290,"accession":"0001493152-21-007950","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-007950","line_url":"/filing/0001493152-21-007950#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Capital Management, LLC; 10X Fund, L.P.","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.16,"price_display":"2.16","price_state":"stated","total_value":21600.0,"total_display":"21,600.00","total_whole":"21,600","shares_owned_after":6316440.0,"shares_owned_after_display":"6,316,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-01","filed_date":"2021-04-05","scope":"insider"},{"id":4635145,"accession":"0001493152-21-005375","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-005375","line_url":"/filing/0001493152-21-005375#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; CZIRR JAMES C; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.31,"price_display":"2.31","price_state":"stated","total_value":23100.0,"total_display":"23,100.00","total_whole":"23,100","shares_owned_after":6326440.0,"shares_owned_after_display":"6,326,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-04","scope":"insider"},{"id":5104895,"accession":"0001493152-21-002719","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-002719","line_url":"/filing/0001493152-21-002719#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Capital Management, LLC; 10X Fund, L.P.","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.04,"price_display":"2.04","price_state":"stated","total_value":20400.0,"total_display":"20,400.00","total_whole":"20,400","shares_owned_after":6336440.0,"shares_owned_after_display":"6,336,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-05","scope":"insider"},{"id":5183440,"accession":"0001493152-21-000241","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-000241","line_url":"/filing/0001493152-21-000241#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"CZIRR JAMES C; 10X Capital Management, LLC; 10X Fund, L.P.","owner_display_name":"CZIRR JAMES C","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.23,"price_display":"2.23","price_state":"stated","total_value":22300.0,"total_display":"22,300.00","total_whole":"22,300","shares_owned_after":6346440.0,"shares_owned_after_display":"6,346,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-04","filed_date":"2021-01-05","scope":"insider"},{"id":2990850,"accession":"0001493152-20-019507","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-019507","line_url":"/filing/0001493152-20-019507#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC; CZIRR JAMES C","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.97,"price_display":"2.97","price_state":"stated","total_value":29700.0,"total_display":"29,700.00","total_whole":"29,700","shares_owned_after":6356440.0,"shares_owned_after_display":"6,356,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-13","filed_date":"2020-10-15","scope":"insider"},{"id":3304053,"accession":"0001493152-20-000877","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-000877","line_url":"/filing/0001493152-20-000877#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; CZIRR JAMES C; 10X Fund, L.P.","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.97,"price_display":"2.97","price_state":"stated","total_value":29700.0,"total_display":"29,700.00","total_whole":"29,700","shares_owned_after":6375790.0,"shares_owned_after_display":"6,375,790","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-17","filed_date":"2020-01-21","scope":"insider"},{"id":8746870,"accession":"0001493152-19-015454","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-19-015454","line_url":"/filing/0001493152-19-015454#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.; CZIRR JAMES C","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17000.0,"shares_display":"17,000","price_per_share":3.725,"price_display":"3.72","price_state":"stated","total_value":63325.0,"total_display":"63,325.00","total_whole":"63,325","shares_owned_after":6385790.0,"shares_owned_after_display":"6,385,790","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-10","filed_date":"2019-10-15","scope":"insider"},{"id":6640589,"accession":"0001493152-18-009006","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001493152-18-009006","line_url":"/filing/0001493152-18-009006#line-4","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60000.0,"shares_display":"60,000","price_per_share":9.06,"price_display":"9.06","price_state":"stated","total_value":543600.0,"total_display":"543,600.00","total_whole":"543,600","shares_owned_after":2649786.0,"shares_owned_after_display":"2,649,786","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-18","filed_date":"2018-06-20","scope":"insider"},{"id":6640586,"accession":"0001493152-18-009006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001493152-18-009006","line_url":"/filing/0001493152-18-009006#line-3","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15475.0,"shares_display":"15,475","price_per_share":8.47,"price_display":"8.47","price_state":"stated","total_value":131073.25,"total_display":"131,073.25","total_whole":"131,073","shares_owned_after":2709786.0,"shares_owned_after_display":"2,709,786","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-15","filed_date":"2018-06-20","scope":"insider"},{"id":6640583,"accession":"0001493152-18-009006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-18-009006","line_url":"/filing/0001493152-18-009006","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":76385.0,"shares_display":"76,385","price_per_share":8.275622177129017,"price_display":"8.28","price_state":"stated","total_value":632133.4,"total_display":"632,133.40","total_whole":"632,133","shares_owned_after":2725261.0,"shares_owned_after_display":"2,725,261","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-14","filed_date":"2018-06-20","scope":"insider","n_lines":2},{"id":6503955,"accession":"0001493152-18-008739","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001493152-18-008739","line_url":"/filing/0001493152-18-008739","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":208140.0,"shares_display":"208,140","price_per_share":7.174381666186221,"price_display":"7.17","price_state":"stated","total_value":1493275.8,"total_display":"1,493,275.80","total_whole":"1,493,276","shares_owned_after":2829786.0,"shares_owned_after_display":"2,829,786","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-13","filed_date":"2018-06-14","scope":"insider","n_lines":4},{"id":6028616,"accession":"0001493152-18-008550","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-18-008550","line_url":"/filing/0001493152-18-008550","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Capital Management, LLC; 10X Fund, L.P.","owner_display_name":"10X Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":110000.0,"shares_display":"110,000","price_per_share":5.88,"price_display":"5.88","price_state":"stated","total_value":646800.0,"total_display":"646,800.00","total_whole":"646,800","shares_owned_after":3009786.0,"shares_owned_after_display":"3,009,786","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-08","filed_date":"2018-06-12","scope":"insider","n_lines":2},{"id":6591823,"accession":"0001493152-18-008235","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-18-008235","line_url":"/filing/0001493152-18-008235#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8093.0,"shares_display":"8,093","price_per_share":5.13,"price_display":"5.13","price_state":"stated","total_value":41517.09,"total_display":"41,517.09","total_whole":"41,517","shares_owned_after":3119786.0,"shares_owned_after_display":"3,119,786","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-04","filed_date":"2018-06-05","scope":"insider"},{"id":6591821,"accession":"0001493152-18-008235","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-18-008235","line_url":"/filing/0001493152-18-008235#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":null,"owner_name":"10X Fund, L.P.; 10X Capital Management, LLC","owner_display_name":"10X Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41907.0,"shares_display":"41,907","price_per_share":5.12,"price_display":"5.12","price_state":"stated","total_value":214563.84,"total_display":"214,563.84","total_whole":"214,564","shares_owned_after":3161693.0,"shares_owned_after_display":"3,161,693","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-01","filed_date":"2018-06-05","scope":"insider"}],"collapsed":true,"next_cursor":"2018-06-01|6591821","ledger_fault":false,"count":{"value":1,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":1,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":1},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001133416","name":"GALECTIN THERAPEUTICS INC","url":"/issuer/0001133416","role":"Ten percent owner","n_filings":36,"first_seen":"2013-10-09","last_seen":"2025-12-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001453356","retrieved_at":"2026-08-23T01:44:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}